NPI 1255767513: Open Payments
NPI 1255767513. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$410 in 13 payments from 5 companies in 2025. Trend: 2023 $112 · 2024 $244 · 2025 $410
Food & beverage: $410
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $209 |
| Supernus Pharmaceuticals, Inc. | 2 | $103 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
Products named: VRAYLAR, Qelbree, REXULTI, CAPLYTA, Auvelity.
